Cantor Fitzgerald Predicts MannKind FY2025 Earnings

MannKind Co. (NASDAQ:MNKD - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for MannKind in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer expects that the biopharmaceutical company will post earnings per share of $0.34 for the year. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

Other analysts have also issued research reports about the company. StockNews.com lowered MannKind from a "buy" rating to a "hold" rating in a research note on Saturday, December 7th. Royal Bank of Canada raised shares of MannKind from a "sector perform" rating to an "outperform" rating and lifted their target price for the company from $7.00 to $10.00 in a research note on Thursday, December 19th. Finally, Wells Fargo & Company assumed coverage on shares of MannKind in a research note on Friday, December 20th. They issued an "overweight" rating and a $9.00 price target for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, MannKind currently has a consensus rating of "Buy" and a consensus price target of $9.07.

MannKind Trading Up 1.3 %

Shares of MNKD stock traded up $0.08 during trading hours on Thursday, reaching $6.03. The company's stock had a trading volume of 1,387,574 shares, compared to its average volume of 2,082,042. MannKind has a one year low of $3.17 and a one year high of $7.63. The stock has a market capitalization of $1.66 billion, a P/E ratio of 86.14 and a beta of 1.29. The firm's fifty day simple moving average is $6.49 and its 200 day simple moving average is $6.26.

MannKind (NASDAQ:MNKD - Get Free Report) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.04. The company had revenue of $70.08 million for the quarter, compared to analysts' expectations of $77.27 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%.

Insider Buying and Selling

In other MannKind news, Director Steven B. Binder sold 67,539 shares of the business's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $6.76, for a total value of $456,563.64. Following the sale, the director now directly owns 1,075,026 shares of the company's stock, valued at approximately $7,267,175.76. The trade was a 5.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Stuart A. Tross sold 55,000 shares of the firm's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total value of $403,700.00. Following the transaction, the insider now owns 967,191 shares of the company's stock, valued at $7,099,181.94. The trade was a 5.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 190,075 shares of company stock valued at $1,325,587 over the last quarter. Corporate insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On MannKind

A number of institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its position in MannKind by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 58,475 shares of the biopharmaceutical company's stock valued at $376,000 after acquiring an additional 5,585 shares in the last quarter. New Wave Wealth Advisors LLC increased its position in shares of MannKind by 78.6% during the 4th quarter. New Wave Wealth Advisors LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $322,000 after purchasing an additional 22,000 shares during the last quarter. 180 Wealth Advisors LLC lifted its stake in shares of MannKind by 1.0% in the 4th quarter. 180 Wealth Advisors LLC now owns 2,105,707 shares of the biopharmaceutical company's stock worth $13,540,000 after purchasing an additional 21,170 shares during the period. Principal Financial Group Inc. increased its holdings in MannKind by 401.8% during the third quarter. Principal Financial Group Inc. now owns 168,518 shares of the biopharmaceutical company's stock valued at $1,060,000 after buying an additional 134,937 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in MannKind by 3.0% in the third quarter. Franklin Resources Inc. now owns 160,016 shares of the biopharmaceutical company's stock worth $1,047,000 after acquiring an additional 4,603 shares during the period. Hedge funds and other institutional investors own 49.55% of the company's stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.